Bispecific antibody mimicking factor VIII

Thrombosis Research

Volumn 141, Issue , 2016, Pages S34-S35

  Nogami, Keiji ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

bispecific antibody; clinical study; factor IX; factor VIII; factor X; Hemophilia

Indexed keywords

ACE 910; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9A; EMICIZUMAB; HEMOSTATIC AGENT; MONOCLONAL ANTIBODY;

ANTIBODY SCREENING; ANTIGENICITY; ARTICLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEMOPHILIA A; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; SUBSTITUTION THERAPY; TREATMENT DURATION; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); HEMORRHAGE; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; FACTOR IXA; FACTOR VIII; FACTOR X; HEMOPHILIA A; HEMORRHAGE; HEMOSTATICS; HUMANS;

EID: 84989862751     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(16)30361-9     Document Type: Article

References (11)

1. 1 Lenting, PJ, Donath, MJ, van Mourik, JA, Mertens, K, Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 269 (1994), 7150–7155.
2. 2 Lapan, KA, Fay, PJ, Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 272 (1997), 2082–2088.
3. 3 Fay, PJ, Koshibu, K, The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 273 (1998), 19049–19054.
4. 4 Kitazawa, T, Igawa, T, Sampei, Z, Muto, A, Kojima, T, Soeda, T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 18 (2012), 1570–1574.
5. 5 Sampei, Z, Igawa, T, Soeda, T, Okuyama-Nishida, Y, Moriyama, C, Wakabayashi, T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One, 8, 2013, e57479.
6. 6 Muto, A, Yoshihashi, K, Takeda, M, Kitazawa, T, Soeda, T, Igawa, T, et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost 12 (2014), 206–213.
7. 7 Muto, A, Yoshihashi, K, Takeda, M, Kitazawa, T, Soeda, T, Igawa, T, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 124 (2014), 3165–3171.
8. 8 Shima, M, Uchida, N, Sanbe, T, Yoneyama, K, Miwa, H, Fukazawa, N, et al. The safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, demonstrated in healthy adults. Haemophilia, 20(Suppl 3), 2014, 76.
9. 9 Shima, M, Hanabusa, H, Taki, M, Matsushita, T, Sato, T, Fukutake, K, et al. Long-term safety and prophylactic efficacy of once-weekly subcutaneous administration of ACE910 in Japanese hemophilia A patients with and without FVIII inhibitors: interim results of the extension study of a phase 1 study. J Thromb Haemost, 13(Suppl 2), 2015, AS017.
10. 10 Uchida, N, Sambe, T, Yoneyama, K, Fukazawa, N, Kawanishi, T, Kobayashi, S, Shima, M, A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 127 (2016), 1633–1641.
11. 11 JAPIC Clinical Trials, JapicCTI-153041. http://www.clinicaltrials.jp/user/cte-Search_e.jsp [Last access date: 27. October, 2015].